Home / Health / New Hair Loss Drug Shows Major Growth
New Hair Loss Drug Shows Major Growth
8 Dec
Summary
- Clascoterone shows strong hair growth results in men's baldness trials.
- Topical drug blocks DHT locally, avoiding systemic hormonal side effects.
- Trials show significant hair count increases, with a favorable safety profile.
A potential breakthrough in treating male pattern baldness has emerged with Clascoterone, a topical anti-androgen. Announced by Cosmo Pharmaceuticals in late 2025, the drug delivered strong hair growth results in two Phase III trials. It works by blocking dihydrotestosterone (DHT) directly at the scalp, aiming to restore hair without the systemic hormonal side effects associated with oral treatments.
The recent trials demonstrated significant increases in hair counts compared to placebo, with one reporting a 539% relative increase. Crucially, Clascoterone's topical application and rapid metabolism suggest minimal systemic absorption, leading to a favorable safety profile comparable to placebo and avoiding the risks of oral DHT blockers.
If approved, Clascoterone could be the first new topical treatment in 30 years. While promising, further long-term data and regulatory review are pending. It is expected to benefit men with early to mid-stage androgenetic alopecia seeking a safer, scalp-focused alternative.
